Ameriprise Financial Inc Enanta Pharmaceuticals Inc Transaction History

Ameriprise Financial Inc

$364 Billion
Q2 2024

A detailed history of Ameriprise Financial Inc transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 29,938 shares of ENTA stock, worth $300,876. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,938

Previous 31,873 6.07%

Holding current value

$300,876

Previous $556,000 30.22%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$11.43 - $17.02 $22,117 - $32,933	-1,935 Reduced 6.07%	29,938 $388,000
Q1 2024 May 15, 2024	SELL	$10.08 - $17.46 $622,228 - $1.08 Million	-61,729 Reduced 65.95%	31,873 $556,000
Q4 2023 Feb 14, 2024	BUY	$8.18 - $10.78 $401,646 - $529,308	49,101 Added 110.34%	93,602 $880,000
Q3 2023 Nov 14, 2023	SELL	$11.09 - $22.13 $769,912 - $1.54 Million	-69,424 Reduced 60.94%	44,501 $497,000
Q2 2023 Aug 14, 2023	SELL	$20.68 - $39.85 $59,847 - $115,325	-2,894 Reduced 2.48%	113,925 $2.44 Million
Q1 2023 May 15, 2023	SELL	$38.82 - $54.59 $57,104 - $80,301	-1,471 Reduced 1.24%	116,819 $4.72 Million
Q4 2022 Feb 14, 2023	SELL	$40.77 - $53.73 $134,337 - $177,040	-3,295 Reduced 2.71%	118,290 $5.5 Million
Q3 2022 Nov 14, 2022	BUY	$48.29 - $71.27 $1.19 Million - $1.76 Million	24,712 Added 25.51%	121,585 $6.31 Million
Q2 2022 Aug 15, 2022	SELL	$38.13 - $76.93 $196,026 - $395,497	-5,141 Reduced 5.04%	96,873 $4.58 Million
Q1 2022 May 16, 2022	BUY	$56.06 - $74.11 $33,187 - $43,873	592 Added 0.58%	102,014 $7.26 Million
Q4 2021 Feb 14, 2022	BUY	$60.19 - $97.37 $9,269 - $14,994	154 Added 0.15%	101,422 $7.58 Million
Q3 2021 Nov 15, 2021	SELL	$41.02 - $58.65 $96,684 - $138,238	-2,357 Reduced 2.27%	101,268 $5.75 Million
Q2 2021 Aug 16, 2021	SELL	$43.76 - $53.11 $226,501 - $274,897	-5,176 Reduced 4.76%	103,625 $4.56 Million
Q1 2021 May 17, 2021	SELL	$41.69 - $54.95 $91,342 - $120,395	-2,191 Reduced 1.97%	108,801 $5.37 Million
Q4 2020 Feb 12, 2021	SELL	$41.16 - $47.47 $20.4 Million - $23.6 Million	-496,574 Reduced 81.73%	110,992 $4.67 Million
Q3 2020 Nov 16, 2020	BUY	$43.36 - $53.53 $2.13 Million - $2.63 Million	49,060 Added 8.78%	607,566 $27.8 Million
Q2 2020 Aug 14, 2020	BUY	$46.37 - $57.58 $16.2 Million - $20.2 Million	350,218 Added 168.14%	558,506 $28 Million
Q1 2020 May 15, 2020	BUY	$40.22 - $62.0 $4.14 Million - $6.39 Million	103,005 Added 97.84%	208,288 $10.7 Million
Q4 2019 Feb 14, 2020	SELL	$57.95 - $66.61 $157,044 - $180,513	-2,710 Reduced 2.51%	105,283 $6.5 Million
Q3 2019 Nov 14, 2019	SELL	$60.08 - $88.17 $28.3 Million - $41.5 Million	-470,337 Reduced 81.33%	107,993 $6.49 Million
Q2 2019 Aug 14, 2019	BUY	$81.3 - $97.35 $5.53 Million - $6.62 Million	68,022 Added 13.33%	578,330 $48.8 Million
Q1 2019 May 15, 2019	BUY	$69.08 - $105.66 $17.8 Million - $27.2 Million	257,840 Added 102.13%	510,308 $48.7 Million
Q4 2018 Feb 14, 2019	BUY	$65.41 - $84.65 $1.88 Million - $2.44 Million	28,790 Added 12.87%	252,468 $17.9 Million
Q3 2018 Nov 14, 2018	BUY	$85.46 - $126.37 $6.5 Million - $9.62 Million	76,092 Added 51.56%	223,678 $19.1 Million
Q2 2018 Aug 14, 2018	BUY	$81.85 - $120.51 $209,536 - $308,505	2,560 Added 1.77%	147,586 $17.1 Million
Q1 2018 May 15, 2018	SELL	$57.91 - $92.15 $466,001 - $741,531	-8,047 Reduced 5.26%	145,026 $11.7 Million
Q4 2017 Feb 12, 2018	BUY	$45.65 - $59.37 $422,536 - $549,528	9,256 Added 6.44%	153,073 $8.98 Million
Q3 2017 Nov 07, 2017	BUY	$37.91 - $46.8 $5.45 Million - $6.73 Million	143,817	143,817 $6.73 Million

Others Institutions Holding ENTA

# of Institutions

Shares Held

21.2M

Call Options Held

10.4K

Put Options Held

2.3K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $208M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account

Ameriprise Financial Inc Enanta Pharmaceuticals Inc Transaction History